Clinical Trials Browser

Anemia, Bone Marrow Diseases, Hematologic Diseases, Myeloproliferative Disorders, Polycythemia Vera, Splenomegaly, Thrombocythemia, Essential, Thrombocytopenia, Primary Myelofibrosis

NCT03003273 2019-02-01

DALFEN

Phase 3 Terminated

142 enrolled

Classical hematology

Neoplasms, Febrile Neutropenia

NCT00109538 2015-05-01

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Phase 3 Terminated

47 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01164046 2014-12-03

Longheva

Phase 3 Terminated

56 enrolled

Classical hematology

Neoplasms, Venous Thrombosis, Venous Thromboembolism

NCT00785356 2014-08-21

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

8 enrolled 1 chart

Classical hematology

Anemia, Leiomyoma

NCT00074763 2012-08-02

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Phase 3 Terminated

4 enrolled

Classical hematologyLymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoma, Thrombocytopenia

NCT00501345 2012-08-01

Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Phase 3 Terminated

5 enrolled 2 charts

Classical hematology

Myocardial Infarction, Thrombocytopenia, Acute Coronary Syndrome

NCT01343680 2012-05-30

Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients

Phase 3 Terminated

2 enrolled

Classical hematology

Anemia, Aplastic, Metabolic Diseases, Neoplasms

NCT00210730 2011-06-10

The Duration Study

Phase 3 Terminated

2 enrolled

Classical hematology

Anemia, Neoplasms

NCT00246597 2011-05-19

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Phase 3 Terminated

37 enrolled

BreastClassical hematology

Anemia, Breast Neoplasms, Red-Cell Aplasia, Pure

NCT00350090 2011-05-19

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Phase 3 Terminated

98 enrolled

Classical hematology

Anemia, Neoplasms

NCT00083434 2011-04-27

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Phase 3 Terminated

Classical hematology

Anemia, Neoplasms

NCT00083486 2011-04-27

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Phase 3 Terminated

Classical hematology

Anemia

NCT00189371 2005-09-19

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

Phase 3 Terminated

300 enrolled

Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Anemia

Clinical Trials

ASTER

Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

PROVE

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

DALFEN

Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)

Longheva

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Aspirin in Patients With Myocardial Infarction and Thrombocytopenia

Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients

The Duration Study

A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum